For long a large number of studies have been focused on identifying the prognostic value of Ezrin in solid tumors and most studies suggest that Ezrin is beneficial for tumor growth and, therefore, associated with poor prognosis including carcinomas of the breast [6], soft tissue sarcoma [7], ovary cancer [8], Gastrointestinal stromal tumors [9],colorectal cancer [10] and non-small cell lung cancer [11]. This evidence concerns the gene EZR and gastrointestinal stromal tumor.